benefici
effect
vivo
diethylcarbamazin
n
carboxamid
dec
treatment
prevent
felin
leukemia
viru
infect
cat
one
anim
model
aid
report
elsewher
benefit
includ
increas
titer
serum
antibodi
felin
oncornavirusassoci
cell
membran
antigen
focma
high
titer
serum
antibodi
focma
felv
cat
associ
resist
felvrel
nine
cat
test
neg
treatment
test
posit
serum
dilut
geometr
mean
titer
gmt
antibodi
focma
dec
treatment
among
cat
initi
test
posit
focma
antibodi
higher
titer
note
treatment
pretreat
gmt
cat
posttreat
gmt
administr
dec
week
one
dose
felv
vaccin
increas
titer
durat
tcorrespond
address
dr
l
w
kttchen
experi
prompt
data
two
earlier
investig
suggest
dec
opson
effect
microfilaria
first
viva
use
dec
result
rapid
fall
circul
microfilaria
cotton
rat
experiment
infect
litomosoid
curinii
due
hepat
sequestr
second
vitro
studi
dec
shown
facilit
microfilari
adher
peripher
blood
cell
presenc
serum
contain
antibodi
microfilari
action
dec
may
independ
decinduc
kill
microfilaria
data
rais
sever
import
question
immedi
relev
current
aid
research
first
could
dec
benefit
preventingtr
retrovir
infect
either
alon
combin
antiretrovir
drug
azt
second
widelypract
use
dec
antifilari
agent
among
african
popul
alter
serolog
outcom
african
enrol
hiv
vaccin
trial
third
plan
substitut
ivermectin
recent
introduc
antifilari
agent
dec
result
increas
hivrel
morbid
mortal
africa
find
possibl
benefit
dec
investig
effect
vitro
addit
dec
serum
diluent
serum
sampl
cat
test
antibodi
focma
human
test
antibodi
human
immunodefici
viru
type
hivl
sampl
cat
analys
antibodi
focma
five
cat
test
posit
felv
leukocyt
antigen
test
perform
laboratori
veterinari
oncolog
memori
sloankett
cancer
center
new
york
citi
usa
describ
previous
five
high
titer
serum
infecti
viru
assay
fisching
lo
remain
five
cat
specif
pathogenfre
breed
coloni
known
felvnaiv
five
test
neg
felv
leukocyt
antigen
serum
infecti
viru
human
serum
sampl
test
antibodi
hiv
enzym
immunoassay
eia
asymptomat
person
test
neg
hiv
antibodi
ripsdspag
includ
blood
bank
donor
dialysi
patient
hemophiliac
io
wive
seroneg
hemophiliac
remain
sampl
test
posit
hiv
antibodi
ripsdspag
includ
sampl
hemophiliac
two
wive
seroposit
hemophiliac
six
nonhemophiliac
patient
asymptomat
person
patient
aidsrel
diseas
seven
addit
serum
sampl
aid
patient
test
western
blot
hiv
antibodi
profil
tihodv
assay
serum
antibodi
focma
determin
indirect
membran
immunofluoresc
imi
cell
use
iofold
dilut
serum
phosphatebuff
salin
exhaust
absorpt
sampl
freshli
isol
normal
felin
lymphocyt
antibodi
titer
report
highest
serum
dilut
observ
cell
fluoresc
serum
sampl
person
test
antibodi
hiv
ripsdspag
use
htlviii
infect
cell
abbott
antibodi
hivl
htlviii
enzym
immunoassay
eia
absorb
valu
determin
quantum
ii
analyz
abbott
laboratori
north
chicago
il
usa
ripsdspag
analysi
perform
harvard
school
public
health
describ
previous
felin
sampl
analys
imi
human
sampl
analys
eia
addit
seven
human
sampl
test
western
blot
dupont
compani
wilmington
de
usa
simultan
test
addit
dec
serum
diluent
ph
correct
n
naoh
serum
incub
phase
assay
solut
permit
high
concentr
dissolv
drug
medic
unmed
serum
diluent
solut
filter
pm
filter
prior
use
order
remov
debri
analys
tcell
subset
perform
blood
lymphocyt
sampl
use
monoclon
antibodi
helperinduc
cell
suppressorcytotox
cell
total
cell
vitro
addit
dec
result
detect
antibodi
focma
dilut
five
five
serum
sampl
felvinfect
cat
wherea
five
sampl
test
neg
dilut
without
dec
antibodi
focma
detect
serum
sampl
felvnaiv
cat
without
addit
dec
serum
diluent
addit
dec
serum
diluent
alter
hivi
serolog
profil
background
upon
test
serum
sampl
seven
aid
patient
western
blot
howev
gp
band
western
blot
strip
yield
four
seven
sampl
slightli
intens
addit
dec
result
regard
addit
dec
serum
diluent
test
antibodi
hiv
eia
appear
tabl
sampl
person
test
posit
antibodi
hiv
ripsdspag
test
posit
eta
person
seven
patient
aidsrel
diseas
yield
absorb
valu
upper
limit
posit
record
quantum
ii
analyz
without
addit
dec
serum
diluent
omit
statist
analys
remain
sampl
consist
sampl
asymptomat
person
sampl
patient
aidsrel
diseas
dec
differ
given
sampl
number
obtain
subtract
absorb
valu
yield
sampl
without
dec
absorb
valu
gener
sampl
dec
dec
differ
posit
asymptomat
case
neg
remaind
null
hypothesi
median
distribut
dec
differ
test
altern
hypothesi
median
mean
onetail
sign
test
use
normal
approxim
continu
correct
level
signific
null
hypothesi
reject
dec
differ
posit
aidsrel
patient
neg
remaind
correspond
sign
test
group
use
binomi
distribut
reject
null
hypothesi
p
serum
sampl
includ
patient
test
posit
antibodi
puv
glycoprotein
neg
antibodi
gug
geneencod
ripsd
page
dec
differ
posit
patient
neg
remaind
correspond
sign
test
group
reject
null
hypothesi
p
dec
differ
posit
six
remain
sampl
test
posit
antibodi
hivl
gag
err
protein
null
hypothesi
reject
also
includ
among
serum
sampl
sampl
patient
thelperinduc
lymphocyt
per
mm
blood
dec
differ
posit
sampl
correspond
sign
test
group
use
binomi
distribut
reject
null
hypothesi
p
remain
patient
thelperinduc
lymphocyt
per
mm
blood
dec
differ
posit
sampl
neg
remaind
null
hypothesi
reject
among
person
test
neg
antibodi
hiv
ripsdspag
test
posit
eia
without
dec
test
posit
dec
dec
differ
posit
neg
remaind
onetail
sign
test
null
hypothesi
median
reject
null
hypothesi
level
signific
dec
may
consist
enhanc
detect
antibodi
focma
serum
sampl
felv
cat
circul
focma
antigen
report
cat
dec
may
less
dramaticallyconsist
improv
detect
antibodi
hiv
patient
serum
sampl
may
also
contain
hiv
antigen
dec
may
enhanc
bind
hiv
antibodi
hiv
serum
antigen
addit
hiv
antigen
use
commerci
assay
howev
dec
h
vitro
increas
absorb
valu
gener
hiv
antibodi
test
serum
sampl
eia
patient
aidsrel
diseas
patient
test
posit
ewr
geneencod
glycoprotein
gag
geneencod
protein
hivi
patient
thelper
lymphocyt
per
mm
blood
three
group
includ
significantli
immunocompromis
hivl
infect
patient
one
possibl
explan
find
rate
viw
hivi
genet
changesapproxim
io
nucleotid
substitut
per
site
per
year
env
iofold
fewer
gq
may
prevent
hivinfect
immunocompromis
patient
mount
optim
serolog
respons
late
stage
hiv
infect
patient
serum
sampl
could
contain
antibodi
bind
circul
variant
hiv
glycoprotein
antigen
bind
less
variant
hiv
glycoprotein
use
commerci
kit
dec
could
enhanc
latter
process
hypothesi
could
also
explain
band
western
blot
use
serum
sampl
four
seven
aid
patient
slightli
intensifi
dec
ad
vitro
regard
use
dec
vitro
optim
detect
antibodi
hivl
glycoprotein
may
import
success
differenti
diagnosi
patient
aid
aidsrel
diseas
immunocompromis
hivl
infect
patient
sinc
patient
may
low
amount
antibodi
even
lower
undetect
amount
antibodi
conceiv
observ
increas
focma
antibodi
felv
cat
viw
dec
treatment
may
augment
increas
antigen
antibodi
interact
demonstr
vitro
high
concentr
drug
data
regard
bodi
fluid
concentr
dec
follow
administr
drug
cat
known
us
whether
dec
increas
retrovir
antigenimmun
host
cell
interact
result
increas
humor
respons
shown
connect
dec
treatment
human
filariasi
requir
studi
effect
appear
like
sinc
dec
increas
focma
antibodi
titer
felvvaccin
cat
mechan
dec
might
enhanc
antigen
antibodi
antigenimmun
host
ceil
interact
unknown
sinc
vivo
dec
treatment
alter
titer
serum
antibodi
nonretrovirus
result
also
may
implic
strategi
improv
assay
antibodi
nonretrovir
infecti
agent
relat
antigen
